Fintel on MSN10h
HC Wainwright & Co. Downgrades Sutro Biopharma (STRO)
Fintel reports that on March 17, 2025, HC Wainwright & Co. downgraded their outlook for Sutro Biopharma (NasdaqGM:STRO) from ...
H.C. Wainwright says competitor data builds optimism for NextCure’s LNCB74
H.C. Wainwright says that competitor data demonstrate impressive ORR in endometrial cancer, opening a potential opportunity for NetCure’s ...
Fintel on MSN13h
HC Wainwright & Co. Initiates Coverage of Actuate Therapeutics (ACTU) with Buy Recommendation
Fintel reports that on March 17, 2025, HC Wainwright & Co. initiated coverage of Actuate Therapeutics (NasdaqGM:ACTU) with a ...
Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs ...
H.C. Wainwright Sticks to Their Hold Rating for Biotricity (BTCY)
In a report released today, Kevin Dede from H.C. Wainwright maintained a Hold rating on Biotricity (BTCY – Research Report). The company’s ...
HC Wainwright Reaffirms “Buy” Rating for Akebia Therapeutics (NASDAQ:AKBA)
HC Wainwright restated their buy rating on shares of Akebia Therapeutics (NASDAQ:AKBA – Free Report) in a research report released on Friday,Benzinga reports. The brokerage currently has a $7.50 ...
Atyr PHARMA (NASDAQ:ATYR) Earns “Buy” Rating from HC Wainwright
HC Wainwright reissued their buy rating on shares of Atyr PHARMA (NASDAQ:ATYR – Free Report) in a research note published on Friday morning,Benzinga reports. They currently have a $35.00 price ...